To confirm that the lipotecan-based CRT regimen enhanced cancer immunogenicity and recruitment of T cells into the tumor microenvironment, we evaluated the levels of H2k1, Tap1 (transporter associated with antigen processing 1), and B2m (β2-microglobulin, which is a component of the MHC class I molecule) by qRT-PCR (Figure 5A–C). This evidence concerns the gene HLA-G and cancer.